Laboratorios Farmaceuticos Rovi S.A. Logo

Laboratorios Farmaceuticos Rovi S.A.

ISIN: ES0157261019 | Ticker: ROVI | LEI: 95980020140005936480
Sector: Health CareSub-Industry: Pharmaceuticals
Country: Spain

About Laboratorios Farmaceuticos Rovi S.A.

Company Description

ROVI is a fully integrated Spanish specialty pharmaceutical company engaged in the research, development, in-licensing, manufacturing and marketing of small molecule and specialty biologic drugs.

To date, thanks to our 22 alliances with international partners, our principal product, Bemiparin, is now present in more than 55 countries.

With our Enoxaparin Biosimilar, we hope to increase our presence in Europe, the United States and emerging countries.

Year founded

1946

Served area

Worldwide

Headcount

1,209

Headquarters

Cl Julian Camarillo 35, 28037 Madrid – Spain

Financial statements

Download as Excel
Line item in (eur) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Assets N/A 574,439,000.00 732,676,000.00 878,703,000.00
Noncurrent Assets N/A 209,861,000.00 226,314,000.00 255,630,000.00
Property Plant And Equipment N/A 155,395,000.00 181,775,000.00 215,541,000.00
Intangible Assets Other Than Goodwill N/A 41,413,000.00 38,558,000.00 35,744,000.00
Investments In Joint Ventures Accounted For Using Equity Method N/A 1,812,000.00 1,994,000.00 2,193,000.00
Noncurrent Receivables N/A 65,000.00 65,000.00 65,000.00
Deferred Tax Assets N/A 11,105,000.00 3,850,000.00 2,078,000.00
Noncurrent Investments In Equity Instruments Designated At Fair Value Through Other Comprehensive Income N/A 71,000.00 72,000.00 9,000.00
Current Assets N/A 364,578,000.00 506,362,000.00 623,073,000.00
Inventories N/A 227,199,000.00 245,473,000.00 311,944,000.00
Trade And Other Current Receivables N/A 76,401,000.00 150,172,000.00 180,011,000.00
Current Prepaid Expenses N/A 13,000.00 1,791,000.00 2,025,000.00
Current Tax Assets Current N/A 7,803,000.00 9,891,000.00 4,148,000.00
Cash and cash equivalents 67,426,000.00 53,162,000.00 99,035,000.00 124,945,000.00
Equity And Liabilities N/A 574,439,000.00 732,676,000.00 878,703,000.00
Equity 322,386,000.00 373,700,000.00 470,976,000.00 521,379,000.00
Issued Capital N/A 3,364,000.00 3,364,000.00 3,241,000.00
Share Premium N/A 87,636,000.00 87,636,000.00 87,636,000.00
Treasury Shares N/A 20,185,000.00 66,121,000.00 27,561,000.00
Other Reserves N/A -3,000.00 -2,000.00 N/A
Statutory Reserve N/A 673,000.00 673,000.00 673,000.00
Equity Attributable To Owners Of Parent N/A N/A 470,976,000.00 520,012,000.00
Noncontrolling Interests N/A N/A 0.00 1,367,000.00
Liabilities N/A 200,739,000.00 261,700,000.00 357,324,000.00
Noncurrent Liabilities N/A 77,850,000.00 71,312,000.00 63,437,000.00
Noncurrent Contract Liabilities N/A 5,788,000.00 1,460,000.00 1,545,000.00
Noncurrent Deferred Income Other Than Noncurrent Contract Liabilities N/A N/A 2,331,000.00 1,774,000.00
Deferred Tax Liabilities N/A 929,000.00 776,000.00 677,000.00
Longterm Borrowings N/A 68,421,000.00 66,745,000.00 59,441,000.00
Current Liabilities N/A 122,889,000.00 190,388,000.00 293,887,000.00
Trade And Other Current Payables N/A 91,364,000.00 125,173,000.00 165,776,000.00
Current Contract Liabilities N/A 25,005,000.00 57,632,000.00 114,901,000.00
Current Deferred Income Other Than Current Contract Liabilities N/A N/A 485,000.00 485,000.00
Current Tax Liabilities Current N/A 0.00 681,000.00 0.00
Current Borrowings And Current Portion Of Noncurrent Borrowings N/A 6,022,000.00 6,417,000.00 12,725,000.00
Line item in (eur) 01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue 419,961,000.00 648,677,000.00 817,698,000.00
Changes In Inventories Of Finished Goods And Work In Progress -17,659,000.00 -782,000.00 -38,883,000.00
Other Work Performed By Entity And Capitalised N/A 0.00 2,856,000.00
Employee Benefits Expense 74,429,000.00 89,803,000.00 106,522,000.00
Depreciation And Amortisation Expense 19,593,000.00 21,364,000.00 22,871,000.00
Profit Loss From Operating Activities 74,682,000.00 181,392,000.00 255,848,000.00
Finance Income 4,000.00 68,000.00 1,770,000.00
Finance Costs 1,072,000.00 905,000.00 849,000.00
Profit Loss Before Tax 72,581,000.00 182,628,000.00 257,967,000.00
Income Tax Expense Continuing Operations 11,524,000.00 29,551,000.00 58,302,000.00
Profit (loss) 61,057,000.00 153,077,000.00 199,665,000.00
Profit Loss Attributable To Owners Of Parent N/A 153,077,000.00 199,669,000.00
Profit Loss Attributable To Noncontrolling Interests N/A 0.00 -4,000.00
Line item in (eur) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Profit (loss) N/A 61,057,000.00 153,077,000.00 199,665,000.00
Adjustments For Finance Costs N/A 1,072,000.00 905,000.00 849,000.00
Adjustments For Decrease Increase In Inventories N/A -70,398,000.00 -23,427,000.00 -71,591,000.00
Adjustments For Depreciation And Amortisation Expense N/A 19,593,000.00 21,364,000.00 22,871,000.00
Adjustments For Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss N/A 1,772,000.00 4,885,000.00 5,160,000.00
Adjustments For Unrealised Foreign Exchange Losses Gains N/A N/A 0.00 821,000.00
Adjustments For Sharebased Payments N/A 0.00 1,403,000.00 0.00
Interest Paid Classified As Operating Activities N/A 151,000.00 4,000.00 0.00
Income Taxes Paid Refund Classified As Operating Activities N/A -6,038,000.00 -23,861,000.00 -43,889,000.00
Cash Flows From Used In Operating Activities N/A 46,876,000.00 149,441,000.00 237,602,000.00
Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities N/A 63,000.00 33,000.00 78,000.00
Purchase Of Property Plant And Equipment Classified As Investing Activities N/A 39,337,000.00 40,218,000.00 50,719,000.00
Purchase Of Intangible Assets Classified As Investing Activities N/A 355,000.00 722,000.00 669,000.00
Interest Paid Classified As Investing Activities N/A 299,000.00 288,000.00 N/A
Interest Received Classified As Investing Activities N/A 4,000.00 68,000.00 6,000.00
Cash Flows From Used In Investing Activities N/A -39,625,000.00 -40,839,000.00 -57,154,000.00
Proceeds From Issuing Other Equity Instruments N/A N/A 0.00 1,371,000.00
Payments To Acquire Or Redeem Entitys Shares N/A 37,255,000.00 78,785,000.00 177,008,000.00
Proceeds From Borrowings Classified As Financing Activities N/A 1,430,000.00 1,340,000.00 1,399,000.00
Repayments Of Borrowings Classified As Financing Activities N/A 13,179,000.00 6,192,000.00 6,768,000.00
Dividends Paid Classified As Financing Activities N/A 9,700,000.00 21,132,000.00 51,007,000.00
Interest Paid Classified As Financing Activities N/A N/A 288,000.00 291,000.00
Cash Flows From Used In Financing Activities N/A -21,515,000.00 -62,729,000.00 -154,538,000.00
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes N/A -14,264,000.00 45,873,000.00 25,910,000.00
Cash and cash equivalents 67,426,000.00 53,162,000.00 99,035,000.00 124,945,000.00

Please note that some sums might not add up.

Filings & Publications

Insider Trades

Sign up and we will give you access!

Capital markets information

ISIN

ES0157261019

LEI

95980020140005936480

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Sub-Industry

Pharmaceuticals

Listed Stock Exchange

Bolsa de Madrid

Stock Index

IBEX35

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.